Introduction
Nucleostemin (NS), is a nucleolar protein that was initially identified in the neural stem cells of rats (Tsai and McKay, 2002) and in several other cancer cells. It contains two putative guanosine triphosphate (GTP) binding motifs: the N-terminal domain, essential for nucleolar localization, and an acidic C-terminus (Tsai and McKay, 2002) . NS is known to shuttle from the nucleolus to the nucleoplasm when bound to GTP; this shuttling is regulated by multiple control mechanisms (Meng et al., 2006; Ma and Pederson, 2008) . The expression of NS is observed to be high in many cancerous cell types, including squamous cell carcinoma, head and neck cancers (Cada et al., 2007) , oral squamous cells and cervical carcinoma cells (Ye et al., 2008; Yoshida et al., 2011) , renal cell carcinomas (Fan et al., 2006a) , glioblastoma cells (Bao et al., 2016 ), brain cancers (Malakootian et al., 2010) , and prostate cancers (Liu et al., 2008) . A similar higher expression was also observed in embryonic, neural, and hematopoietic stem cells (Tsai and McKay, 2002; Cai et al., 2003; Nomura et al., 2009; Lin et al., 2010; Yamashita et al., 2013; Yuan et al., 2015) . However, interestingly, NS was observed to be downregulated in differentiated cells and noncancerous cells (Tsai and McKay, 2002; Yaghoobi et al., 2005) . From these studies, it is evident that NS plays a role in the cell cycle and proliferation of rapidly dividing cells.
Studies of complete loss of NS, either through siRNA knockdown or proteolytic degradation, lead to p53 upregulation leading to cell cycle arrest or apoptosis, whereas heterozygous loss leads to cellular senescence (Zhu et al., 2006; Huang et al., 2011) . Based on the tumor cell type, depletion or knockdown of NS has been shown to perturb the cell cycle progression either in the G0/G1 phase (U2OS, Saos-2, and HeLa) (Sijin et al., 2004; Ma and Pederson, 2007; Dai et al., 2008; Seyed-Gogani et al., 2014) or in the G2/M phase (PC-3, HCT116, K562, MHCC97H, and bone-marrow-derived stromal stem cells) (Jafarnejad et al., 2008; Liu et al., 2008; Ma and Pederson, 2008; Nikpour et al., 2009; Huang et al., 2015; Yuan et al., 2015) . Loss of NS increased the spontaneous DNA damage in cancer cells by elevating the frequency of telomere damage and aberration, reducing the telomeric length, and perturbing the telomeric repeat binding factor 2 (TRF2 ΔBΔM-)-induced telomeric recruitment of Ras associated with diabetes (RAD51) (Hsu et al., 2012; Lin et al., 2013; Meng et al., 2013; Yamashita et al., 2013) . However, overexpression of NS interferes with cell cycle progression through the p53 pathway (Tsai and McKay, 2002; Dai et al., 2008) .
Parallelly, multiple studies report that NS is expressed even in normal cells and tissues such as renal cells, uroepithelial cells, and oropharyngeal and laryngeal epithelial cells (Fan et al., 2006a; Cada et al., 2007; Nikpour et al., 2009) . This dispute over the expression of NS formed the basis of this study, and it is an attempt to clearly understand the expression pattern and localization of NS in normal and cancer cell lines, which could thus lay the foundation to assess the role of NS in the future. In this study, we observed the expression of NS in both normal (HaCaT, THLE, HEK 293) and cancerous (A431, HepG2, A498, HeLa, IMR32, ACHN, HCT116) cell lines. siRNAmediated silencing of NS revealed that the knockdown of NS reduced the rate of proliferation in HEK 293 (normal renal), THLE (normal liver), and A498 (cancerous renal) cell lines. Furthermore, immunocytochemistry and western blotting analysis revealed that NS differentially localized in normal and cancer cells. From these results, we infer that loss of NS inhibits the proliferation of normal cells similar to that of cancerous cells, and NS may perform functions other than proliferation in the cytoplasm of cancerous cells.
Materials and methods

Cell culture
All the cell lines used in the study were procured from the National Centre for Cell Sciences (NCCS), Pune, India (Table 1 ). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (GIBCO; Thermo Fisher Scientific, Inc., Waltham, MA, USA), supplemented with 10% fetal bovine serum (FBS) (GIBCO, UK) and antibiotic-antimycotic solution (GIBCO, UK), and were maintained at 37 °C in a humidified incubator with 5% CO 2 .
RNA isolation and RT-PCR
The total RNA from all the cancer and normal cell lines was extracted using TRIzol (Ambion, Life Technologies, USA) and quantified using the NanoDrop system (NanoDrop Lite Spectrophotometer, Thermo Scientific, USA). The extracted RNA was treated with RNase-free DNase (NEB, UK) and incubated at 28 °C for 1 h and deactivated at 70 °C for 10 min. One microgram of RNA was reverse transcribed to synthesize cDNA using oligo (dT) and Moloney murine leukemia virus (Mo-MLV) reverse transcriptase (NEB, UK). PCR primers were designed using Primer3 software and the primer sequences of the genes are shown in Table 2 . PCR amplification was performed using a thermal cycler (Eppendorf, Hamburg, Germany) with the following conditions: initial denaturation at 95 °C for 2 min, followed by 30 cycles of 95 °C for 20 s, 58 °C for 30 s, and 72 °C for 30 s. β-Actin was used as the internal control. PCR products were separated on a 1% agarose gel and viewed under a UV transilluminator.
siRNA transfection
The siRNA targeting NS and nontargeting control siRNA were purchased from QIAGEN (USA). The day before transfection, the cells were cultured and seeded in 24-well plates. The HEK 293, THLE, and A498 cell lines were transfected with 65 nM siRNA and 3 µL of HiPerFect transfection reagent (QIAGEN, USA) and vortexed with 100 µL of serum-free medium. This mixture was incubated for 10 min at room temperature and then added to the cells in the plate. The cells were harvested at 24, 48, and 72 h and subjected to western blotting analysis.
Growth curve analysis
HEK 293, THLE, and A498 cells were transfected with siRNA targeting NS and control siRNA. Growth curve analysis was performed by counting the number of cells in the well every 24 h after transfection over a period of 72 h, using a hemocytometer.
MTT assay/cell proliferative assay
The MTT assay was used to evaluate cell proliferation subsequent to transfection. The cells were cultured overnight in 96-well plates at a density of 5 × 10 3 cells/ well and siRNA transfection was performed. Tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5 mg/mL) was added to the culture medium in each well and incubated for 4 h at 37 °C. The medium was then removed and the formazan crystals were dissolved with 150 µL/well of dimethyl sulfoxide (DMSO). The absorption was measured using an ELISA Reader (Synergy HTX, BioTek) at 570 nm.
Immunocytochemistry
The cells were fixed with 4% paraformaldehyde for 15 min at room temperature, followed by permeabilization with 0.1% Triton X-100. Cellular proteins were then blocked with 1% BSA for 1 h at room temperature and then incubated with primary antibodies overnight in a humidified chamber at 4 °C. After overnight incubation, the cells were washed with PBS and incubated with secondary antibodies for 1 h at room temperature. Anti-NS mouse monoclonal primary antibody (1:200, BD Bioscience, USA), anti-β-actin mouse monoclonal primary antibody (1:200, Santa Cruz Biotechnology, USA), and antimouse secondary antibody (1:400, BD Bioscience, USA) were used for the experiment. The cells were counterstained with 4' ,6-diamidino-2-phenylindole (DAPI). The coverslips were mounted using glycerol and were analyzed in a fluorescence-enabled inverted microscope (Leica Microsystems, USA).
Protein isolation and quantification
The cells were lysed using a radio immunoprecipitation assay (RIPA) buffer (Sigma-Aldrich, USA), kept on ice for 5 min, and centrifuged at ~14,000 × g for 15 min. The total protein was collected and stored. The nuclear and cytoplasmic fractions from the cells were extracted using an NE-PER Nuclear Cytoplasmic Extraction Reagent Kit (Pierce, Rockford, IL, USA) according to the manufacturer's instructions. Proteins isolated were quantified using Bradford reagent (Sigma-Aldrich, USA) based on the Bradford method (Bradford, 1976) .
Western blotting
The total protein, cytoplasmic, and nuclear fractions were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane (Amersham Protran, GE Healthcare Life Sciences, Germany) in a semidry blotting apparatus. The membranes were blocked for 1 h with 3% bovine serum albumin (BSA) in Tris-buffered saline with 0.1% Tween 20 (TBST). The blocked membranes were incubated with anti-NS (562749; 1:1000) (BD Biosciences, USA), anti-β-actin (sc-47778; 1:1000) (Santa Cruz, USA), and Cdk2 (sc-6248; 1:1000) (Santa Cruz, USA) primary antibody, prepared in blocking solution at 4 °C overnight. β-Actin and Cyclin-dependent kinase 2 (Cdk2) were used as the internal control for the total and nuclear fractions, respectively. The membranes were then washed with TBST and incubated with appropriate horseradish peroxidaseconjugated (HRP) secondary antibodies (550946; 1:2000, BD Biosciences, USA) at room temperature for 2 h. The blots were then washed with TBST and were visualized using an enhanced chemiluminescence (ECL) kit (Pierce, USA) and analyzed using a gel image analysis system.
Results
Nucleostemin was abundantly expressed in cancerous cell lines and expressed in detectable levels in normal cell lines
To investigate the NS expression in normal and cancerous cells, RT-PCR analysis was performed on normal cell lines (HaCaT -skin, THLE -liver, and HEK 293 -kidney), which were compared with their cancerous counterparts (A431, HepG2, and A498) from the same organs of origin. The results revealed that NS was expressed in detectable amounts in both normal and cancerous cell lines. However, its expression levels were found to be significantly higher in cancerous cell lines of the skin (A431) ( Figure 1a ) and liver (HepG2) ( Figure 1b ) compared with normal cells. In the kidney cell line (A498), NS expression was found to be lower in the cancerous cells (Figure 1c ).
siRNA-mediated knockdown of nucleostemin inhibited the rate of proliferation of rapidly dividing cancerous as well as normal renal cell lines
The high expression of NS in cancer cell lines A431 and HepG2 could be due to the increased proliferation rate of the cancer cells, and to determine the effect of NS in proliferation of the cell lines, transient silencing of NS was performed on normal renal (HEK 293), normal liver (THLE), and renal carcinoma (A498) cell lines, which were the most rapidly dividing cell lines from our selection. Silencing of the NS gene was achieved by transiently transfected siRNA. To optimize the efficacy of the siRNA, these cell lines were transfected with different concentrations of siNS (40, 50, and 65 nM) and the results revealed that the highest knockdown was obtained with 65 nM concentration of siNS at 72 h after transfection. Silencing of NS was verified using western blotting analysis, which confirmed the highest inhibition at 72 h (Figure 2a) , and no significant downregulation was observed in 24 and 48 h (Supplementary Figure A) . A growth curve plotted with cell numbers counted over a 24-h time plot showed a significant decrease in the proliferation of siNS cells compared to the control for HEK 293, THLE, and A498 cell lines (Figure 2b ). The decrease in proliferation was further confirmed by the MTT assay (Figure 2c ).
Nucleostemin was localized in the nucleus and cytoplasm of both cancerous cells and stem cells
Immunocytochemistry was performed to investigate the localization of NS in normal cells (HaCaT, THLE, and HEK 293), cancerous cell lines (A431, HepG2, and A498), and mesenchymal stem cells (MSCs) derived from dental pulp cells (Figures 3a-3d ). The results revealed that NS was localized in both the cytoplasmic and nuclear compartments of all the stem cells and cancerous cell lines, while being limited only to the nuclei of normal cells (Figure 3e ). Immunoblotting of the NS antibody on fractionated total, nuclear, and cytoplasmic protein samples from these cell lines also confirmed the expression pattern observed in immunocytochemistry. These immunological experiments were also performed on other cancerous cell lines: cervical carcinoma (HeLa), neuroblastoma (IMR32), renal carcinoma (metastatic) (ACHN), colon cancer (HCT116), and human oral squamous cell carcinoma (OSCC) T4 stage cancer tissue samples, which also presented a similar expression pattern of NS (Supplementary Figures B and C) . Interestingly, the immunolocalization analysis of NS in siRNA knockdown cancerous cells (A498) showed a predominant reduction of NS expression in the nucleus (Figure 3f) , with a lower but detectable expression in the cytoplasm.
Discussion
The localization and expression profiles of NS have always been a debated issue in the mechanism of NS action, which was primarily reported as a nucleolar protein identified in stem and cancer cells (Tsai and McKay, 2002; Kafienah et al., 2006; Nomura et al., 2009; Yamashita et al., 2013) . Parallelly, a number of studies of normal renal tissues, uroepithelial cells, and normal oropharyngeal and laryngeal epithelial cells also showed NS expression (Tsai and McKay, 2002; Fan et al., 2006a; Nikpour et al., 2009 ). This study examined this issue by comparing the NS expression and localization profiles in stem cells (MSCs) derived from dental pulp cells, cancerous cells, and normal cells. Earlier studies reported that NS expression levels vary among tissues (Tsai and McKay, 2002; Fan et al., 2006b; Malakootian et al., 2010; Li et al., 2015) , and to analyze this variation profile, RT-PCR was performed for both normal and cancerous cell lines. Overexpression of NS was observed in HEK 293 when compared to the A498 cell line (Figure 1c ) and this might be due to the fact that HEK 293 was derived from the human embryonic kidney and it may retain gene expression traits observed during early development. Since NS expression was observed even in normal cells, it is critical to analyze if the loss of NS would affect the proliferation of normal cells to the extent that it affects the cancerous cell lines. Interestingly, siRNAmediated transient silencing of NS on HEK 293 and A498 cells revealed that loss of NS decreased the proliferation of cancerous and normal cells at similar rates. These results suggest that NS was required for proliferation of not only cancerous cells but also for rapidly dividing noncancerous cells. Innumerable studies have also proven that NS is involved in controlling the proliferation of stem cells McKay, 2002. Beekman et al., 2006; Kafienah et al., 2006; Jafarnejad et al., 2008; Nomura et al., 2009) . NS is primarily reported to be a nucleolar protein that interacts with several proteins, including p53, mouse double minute 2 (MDM2), nucleophosmin (NPM), ribosomal L1 domain containing protein 1 (RSL1D1), telomeric repeat binding factor 1 (TRF1), and alternate reading frame (ARF), thereby involved in self-renewal, cell cycle regulation, pre-RNA processing, apoptosis, and cell proliferation (Bernardi and Pandolfi, 2003; Beekman et al., 2006; Zhu et al., 2006; Pederson, 2007, 2008; Dai et al., 2008; Meng et al., 2008 Meng et al., , 2013 Nomura et al., 2009; Lo and Lu, 2010; Zwolinska et al., 2012) . Since the localization of NS in the nucleus is important for these functions, the variation in the distribution pattern of NS in cancerous and normal cell lines was studied. Earlier studies reported that NS is physically associated with MDM2 and functionally linked to p53 inactivation (Tsai and McKay, 2002; Ma and Pederson, 2007; Dai et al., 2008) , while a few reported that NS remains indispensable for the survival and proliferation of p53 null normal or cancer cells (Beekman et al., 2006; Jafarnejad et al., 2008; Meng et al., 2013) . The p53 properties of all the cell lines used in the study were analyzed, which revealed that the normal skin cell line (HaCaT) had mutated p53, but it is unclear whether p53 activity is still functional regarding induction of apoptosis, whereas the skin carcinoma cell line (A431) has no functional p53 and is highly sensitive to mitogenic signals. The hepatocarcinoma cell line (HepG2) expresses normal p53 levels, while the other cell lines, including normal renal (HEK 293), normal liver (THLE), colon cancer (HCT116), cervical carcinoma (HeLa), neuroblastoma (IMR32), and renal carcinoma (A498, ACHN) cell lines, have wild-type p53. Surprisingly, our immunocytochemistry analysis revealed variation in distribution patterns of NS in normal, cancerous, and stem cells.
As immunofluorescence results can be affected by many factors such as cell morphology, fixation methods, or nonspecific binding of antibodies, the immunofluorescence data were confirmed by immunoblotting by performing subcellular fractionation of the total, nuclear, and cytoplasmic extracts of cells to support the data and ascertain whether the results correlated with the immunofluorescence data. Our data on the localization pattern of NS were concordant with earlier reports on renal cell carcinoma tissues, gastric cancer cells, and colon cancer cells (Han et al., 2005; Yang et al., 2005; Fan et al., 2006c) . Immunolocalization experiments on siRNA-mediated NS inhibited cancerous (A498) (Figure 3f ) and normal (HEK 293) (Supplementary Figure D) cell lines. Interestingly, NS was predominantly downregulated in the nuclei of both cell types. However, a lower but detectable quantity of NS was present in the cytoplasm of cancerous cells. The fact that this cytoplasmic NS could not salvage the proliferation of the cells suggests that NS plays a role other than proliferation when localized in the cytoplasm of cancerous cells. Thus, it is likely that different NS localizations between cancerous/ stem and normal cells may be related to the different functional activities of these cell types. Furthermore, the functional activity of shuttling and specific target genes of this protein between the nucleus and cytoplasm of these cells remains to be resolved and established.
Overall, from this study, we postulate that NS was required for proliferation of not only cancerous cells but also for rapidly dividing noncancerous cells. Furthermore, NS is localized both in the nucleus and cytoplasm of cancerous cell lines, but only in the nucleus of normal cell lines. Thus, we suggest that NS may perform functions other than proliferation in the cytoplasm of cancerous cells. Moreover, evaluating the target genes of these proteins within the nucleus and cytoplasm of these cells could contribute to cancer treatment. 
